Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Piramal Pharma's Debt-to-EBITDA or its related term are showing as below:
NSE:PPLPHARMA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.95 Med: 3.45 Max: 6.3
Current: 5.18
During the past 6 years, the highest Debt-to-EBITDA Ratio of Piramal Pharma was 6.30. The lowest was 2.95. And the median was 3.45.
NSE:PPLPHARMA's Debt-to-EBITDA is ranked worse than 82.7% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.59
vs NSE:PPLPHARMA: 5.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Piramal Pharma Debt-to-EBITDA Related Terms
Piramal Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Piramal Pharma (NSE:PPLPHARMA) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Piramal Pharma. Over the past decade, Piramal Pharma's Debt-to-EBITDA has ranged from 2.95 to 6.30. According to the industry distribution chart, Piramal Pharma ranks #564 out of 682 companies in the Drug Manufacturers industry, placing it in the top 82.7%.
Is Piramal Pharma's Debt-to-EBITDA too high?
Piramal Pharma's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 6.30. Based on the distribution chart, Piramal Pharma ranks #564 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #564 out of 682 companies for Debt-to-EBITDA. This places Piramal Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. Historically, Piramal Pharma's own Debt-to-EBITDA has ranged from 2.95 to 6.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.59, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Piramal Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹191.25, compared to a current price of ₹207.71 — trading 8.6% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Piramal Pharma's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹207.71 is trading 8.6% above its estimated GF Value™ of ₹191.25.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Debt-to-EBITDA: 0.00
GF Value™: ₹191.25 vs. price of ₹207.71 (8.6% above fair value)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score
Get the complete analysis for NSE:PPLPHARMA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
